Watanabe M, Komeshima N, Naito M, Isoe T, Otake N, Tsuruo T
Pharmaceutical Research Laboratory, Kirin Brewery Co., Ltd., Gunma, Japan.
Cancer Res. 1991 Jan 1;51(1):157-61.
We previously reported that MX2, a new morpholino anthracycline, showed marked effects on pleiotropic drug-resistant sublines of murine P388 leukemia in vivo as well as in vitro. In this study we examine the in vitro cytotoxicity against pleiotropic drug-resistant sublines of human tumor cell lines. MX2 was effective against multidrug-resistant sublines of four human tumor cell lines; these cells, having a 4.8- to 200-fold cross-resistance to Adriamycin (ADM) showed only a 0.7- to 2.3-fold resistance to MX2 compared with the sensitive cells. To elucidate the mechanism by which MX2 overcomes multidrug resistance, the intracellular pharmacology of MX2 in human myelogenous leukemia K562 and its ADM-resistant subline (K562/ADM) was examined. Both K562 and K562/ADM cells accumulated MX2 more easily than ADM, and the intracellular accumulation of MX2 attained a steady state in both cell lines within 30 min of incubation at 37 degrees C. The amount of MX2 that accumulated in K562/ADM at a steady state was only 1.3 times lower than that in K562. However, ADM was accumulated slowly in both cell lines compared with MX2, and the intercellular concentration reached a steady state in K562/ADM after 90 min of incubation and in K562 after more than 120 min. K562/ADM cells accumulated a 3.3-fold lower concentration of ADM than K562 after 120 min of exposure. The steady-state concentration of ADM in K562/ADM was 8.3 times lower than that of MX2. In addition, greater than 70% of MX2 was retained in both cell lines after 150 min of incubation in the absence of this drug. Verapamil, a calcium antagonist, hardly augmented the cytotoxicity of MX2 against K562/ADM, and no distinct effect of this drug on both the time course and the maximal level of accumulation of MX2 was observed. Interestingly, MX2 effectively inhibited ATP/Mg2(+)-dependent [3H]vincristine binding to K562/ADM membrane preparations, indicating that MX2 could be transported outside the cell by an active efflux pump. The high intracellular accumulation and retention of MX2 in K562/ADM through the rapid influx of the drug into the cells may be one of the reasons why MX2 circumvents pleiotropic drug resistance.
我们之前报道过,新型吗啉代蒽环类药物MX2在体内和体外对小鼠P388白血病的多药耐药亚系均显示出显著作用。在本研究中,我们检测了MX2对人肿瘤细胞系多药耐药亚系的体外细胞毒性。MX2对四种人肿瘤细胞系的多药耐药亚系有效;这些细胞对阿霉素(ADM)具有4.8至200倍的交叉耐药性,但与敏感细胞相比,对MX2仅表现出0.7至2.3倍的耐药性。为阐明MX2克服多药耐药的机制,我们检测了MX2在人髓性白血病K562及其ADM耐药亚系(K562/ADM)中的细胞内药理学特性。K562和K562/ADM细胞摄取MX2均比摄取ADM更容易,且在37℃孵育30分钟内,两种细胞系中MX2的细胞内摄取均达到稳态。K562/ADM中达到稳态时积累的MX2量仅比K562中的低1.3倍。然而,与MX2相比,ADM在两种细胞系中的积累均较慢,K562/ADM在孵育90分钟后细胞间浓度达到稳态,K562则在孵育120分钟以上后达到稳态。暴露120分钟后,K562/ADM细胞积累的ADM浓度比K562低3.3倍。K562/ADM中ADM的稳态浓度比MX2低8.3倍。此外,在无该药物孵育150分钟后,两种细胞系中均有超过70%的MX2被保留。钙拮抗剂维拉帕米几乎未增强MX2对K562/ADM的细胞毒性,且未观察到该药物对MX2摄取的时间进程和最大水平有明显影响。有趣的是,MX2有效抑制了ATP/Mg2(+)依赖性的[3H]长春新碱与K562/ADM细胞膜制剂的结合,表明MX2可通过主动外排泵转运至细胞外。MX2通过快速流入细胞而在K562/ADM中实现高细胞内积累和保留,这可能是MX2规避多药耐药的原因之一。